Novocral (Ceftazidime)

Novocral (ceftazidime) is employed to manage infections caused by susceptible gram‑negative bacteria, especially in serious systemic disease.

• Pseudomonas aeruginosa infections: effective eradication of this resistant pathogen in severe systemic infections.
• Hospital‑acquired pneumonia: helps resolve lower respiratory tract infections in ventilated patients.
• Complicated urinary tract infections: clears infection when oral agents are ineffective.
• Intra‑abdominal infections: targets mixed flora in peritonitis and postoperative infections.
• Febrile neutropenia: provides broad‑spectrum coverage for at‑risk immunocompromised patients.

• Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, disrupting peptidoglycan cross‑linking. This leads to weakened cell walls and osmotic lysis of susceptible gram‑negative organisms, including Pseudomonas species, resulting in bactericidal activity.

Common side effects are generally mild and reversible.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Rash: skin erythema or mild itching.
• Injection site pain: discomfort at the IM/IV site.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption.
• Neutropenia: marked reduction in neutrophil count.
• Thrombocytopenia: low platelet levels increasing bleeding risk.
• Renal impairment: acute kidney injury, especially with high doses.
• Seizures: risk in patients with pre‑existing CNS disorders or high plasma concentrations.

Before initiating therapy, consider patient‑specific factors and safety measures.

• Renal function: adjust dosing in patients with impaired kidney function.
• Allergy history: avoid in individuals with known cephalosporin hypersensitivity.
• Pregnancy: use only when the potential benefit justifies the potential risk to the fetus.
• Drug interactions: monitor concomitant nephrotoxic or ototoxic agents.
• Superinfection: be aware of the risk of secondary fungal or bacterial infections.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ceftazidime may interact with other medications, requiring careful management.

Major Interactions (Avoid)

• Aminoglycosides: increased risk of nephrotoxicity and ototoxicity.
• Loop diuretics: heightened potential for ototoxic effects.
• Probenecid: reduces renal clearance, raising ceftazidime plasma levels.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Oral contraceptives: possible reduction in contraceptive efficacy.
• Antacids containing aluminum or magnesium: may affect absorption when given orally (less relevant for IV/IM).